Back to top
more

Arrowhead Pharmaceuticals (ARWR)

(Delayed Data from NSDQ)

$28.94 USD

28.94
1,160,019

+0.03 (0.10%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $28.92 -0.02 (-0.07%) 7:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for Arrowhead Pharmaceuticals, Inc falls in the month of September.

All items in Millions except Per Share data.

9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Assets          
Cash & Equivalents 404 376 368 315 259
Receivables 0 1 10 1 1
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 16 27 7 6 6
Total Current Assets 420 405 385 322 265
Net Property & Equipment 290 110 49 31 23
Investments & Advances 0 106 246 137 44
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 10 12 14 15 17
Deposits & Other Assets 0 0 0 0 0
Total Assets 766 692 710 523 350
Liabilities & Shareholders Equity 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 36 3 9 7 8
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 58 59 24 13 11
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 74 111 19 78
Total Current Liabilities 105 139 147 41 97
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 56 132 0 9
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 268 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 478 274 301 61 106
Shareholders Equity 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,300 1,219 1,053 965 664
Retained Earnings -1,026 -821 -645 -504 -419
Other Equity 13 20 0 0 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 287 418 409 462 244
Total Liabilities & Shareholder's Equity 766 692 710 523 350
Total Common Equity 287 418 409 462 244
Shares Outstanding 107.10 105.80 104.20 102.20 94.80
Book Value Per Share 2.68 3.95 3.92 4.52 2.57

Fiscal Year End for Arrowhead Pharmaceuticals, Inc falls in the month of September.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 523 220 404 452
Receivables NA 0 0 0 1
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 19 18 16 17
Total Current Assets NA 542 238 420 470
Net Property & Equipment NA 359 333 290 231
Investments & Advances NA 0 0 0 43
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 9 10 10 11
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 955 626 766 796
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 9 4 36 8
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 51 55 58 43
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 1 0 1 17
Total Current Liabilities NA 65 64 105 70
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 274 268 264
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 460 453 478 414
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,769 1,320 1,300 1,281
Retained Earnings NA -1,284 -1,159 -1,026 -916
Other Equity NA 11 12 13 17
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 495 174 287 382
Total Liabilities & Shareholder's Equity NA 955 626 766 796
Total Common Equity 0 495 174 287 382
Shares Outstanding 124.20 123.90 123.10 107.10 106.90
Book Value Per Share 0.00 4.00 1.41 2.68 3.57